{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T07:17:18Z","timestamp":1792048638051,"version":"4.4.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T00:00:00Z","timestamp":1721088000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T00:00:00Z","timestamp":1721088000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"DOI":"10.1007\/s00296-024-05663-9","type":"journal-article","created":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T04:01:49Z","timestamp":1721102509000},"page":"2205-2212","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Tocilizumab-induced psoriatic eruption : a case report and a case-based review"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8042-5716","authenticated-orcid":false,"given":"Hubert","family":"Nielly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8496-4330","authenticated-orcid":false,"given":"L.","family":"Bial\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9212-0859","authenticated-orcid":false,"given":"L.","family":"Gilardin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6787-718X","authenticated-orcid":false,"given":"T.","family":"Carmoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"\u00c9on","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8262-9085","authenticated-orcid":false,"given":"H.","family":"Vanquaethem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2850-867X","authenticated-orcid":false,"given":"A-C","family":"Fougerousse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,16]]},"reference":[{"key":"5663_CR1","unstructured":"Gagnier J, Kienle G, Altman D, The CARE Guidelines : Consensus-based Clinical Case Reporting Guideline Development"},{"key":"5663_CR2","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1111\/j.1365-2133.2010.10005.x","volume":"163","author":"S Laurent","year":"2010","unstructured":"Laurent S, Le Parc J-M, Cl\u00e9rici T et al (2010) Onset of psoriasis following treatment with tocilizumab: correspondence. Br J Dermatol 163:1364\u20131365. https:\/\/doi.org\/10.1111\/j.1365-2133.2010.10005.x","journal-title":"Br J Dermatol"},{"key":"5663_CR3","doi-asserted-by":"publisher","first-page":"657","DOI":"10.3899\/jrheum.111166","volume":"39","author":"D Wendling","year":"2012","unstructured":"Wendling D, Letho-Gyselinck H, Guillot X, Prati C (2012) Psoriasis Onset with Tocilizumab Treatment for Rheumatoid Arthritis: Fig.\u00a01. J Rheumatol 39:657\u2013657. https:\/\/doi.org\/10.3899\/jrheum.111166","journal-title":"J Rheumatol"},{"key":"5663_CR4","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.jbspin.2013.03.014","volume":"80","author":"A Grasland","year":"2013","unstructured":"Grasland A, Mah\u00e9 E, Raynaud E, Mah\u00e9 I (2013) Psoriasis onset with tocilizumab. Joint Bone Spine 80:541\u2013542. https:\/\/doi.org\/10.1016\/j.jbspin.2013.03.014","journal-title":"Joint Bone Spine"},{"key":"5663_CR5","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1159\/000362266","volume":"228","author":"N Palmou-Fontana","year":"2014","unstructured":"Palmou-Fontana N, S\u00e1nchez Gavi\u00f1o JA, McGonagle D et al (2014) Tocilizumab-induced psoriasiform rash in rheumatoid arthritis. Dermatol Basel Switz 228:311\u2013313. https:\/\/doi.org\/10.1159\/000362266","journal-title":"Dermatol Basel Switz"},{"key":"5663_CR6","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.revmed.2014.01.007","volume":"35","author":"L Sparsa","year":"2014","unstructured":"Sparsa L, Afif N, Bularca S et al (2014) [Paradoxical cutaneous reactions associated with tocilizumab therapy]. Rev Med Interne 35:613\u2013616. https:\/\/doi.org\/10.1016\/j.revmed.2014.01.007","journal-title":"Rev Med Interne"},{"key":"5663_CR7","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1007\/s40278-015-10949-8","volume":"1578","author":"N Klossowski","year":"2015","unstructured":"Klossowski N, Oommen PT, Gerber PA et al (2015) Tocilizumab: scalp psoriasis: case report. React Wkly 1578:282\u2013282. https:\/\/doi.org\/10.1007\/s40278-015-10949-8","journal-title":"React Wkly"},{"key":"5663_CR8","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3121\/cmr.2017.1364","volume":"16","author":"R Sehgal","year":"2018","unstructured":"Sehgal R, Stratman EJ, Cutlan JE (2018) Biologic Agent-Associated Cutaneous adverse events: a single Center experience. Clin Med Res 16:41\u201346. https:\/\/doi.org\/10.3121\/cmr.2017.1364","journal-title":"Clin Med Res"},{"key":"5663_CR9","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.rhum.2017.01.009","volume":"85","author":"A Boursier","year":"2018","unstructured":"Boursier A, S\u00e9journ\u00e9 A, Fardellone P, Go\u00ebb V (2018) Psoriasis paradoxal chez une femme trait\u00e9e par tocilizumab pour une polyarthrite rhumato\u00efde. Rev Rhum 85:510\u2013511. https:\/\/doi.org\/10.1016\/j.rhum.2017.01.009","journal-title":"Rev Rhum"},{"key":"5663_CR10","doi-asserted-by":"publisher","first-page":"3603","DOI":"10.2169\/internalmedicine.3214-19","volume":"58","author":"J Kohro-Kawata","year":"2019","unstructured":"Kohro-Kawata J, Kinjo M (2019) Papulopustular Rash due to Tocilizumab. Intern Med Tokyo Jpn 58:3603\u20133604. https:\/\/doi.org\/10.2169\/internalmedicine.3214-19","journal-title":"Intern Med Tokyo Jpn"},{"key":"5663_CR11","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1159\/000504429","volume":"11","author":"Y Matsushima","year":"2019","unstructured":"Matsushima Y, Hayashi A, Mizutani K et al (2019) Psoriasiform Dermatitis developing during treatment of juvenile idiopathic arthritis with Tocilizumab. Case Rep Dermatol 11:317\u2013321. https:\/\/doi.org\/10.1159\/000504429","journal-title":"Case Rep Dermatol"},{"key":"5663_CR12","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s00296-018-4175-1","volume":"39","author":"M Hayakawa","year":"2019","unstructured":"Hayakawa M, Izumi K, Higashida-Konishi M et al (2019) Tocilizumab-induced psoriasis-like eruption resolved by shortening the dose interval in a patient with rheumatoid arthritis: a case-based review. Rheumatol Int 39:161\u2013166. https:\/\/doi.org\/10.1007\/s00296-018-4175-1","journal-title":"Rheumatol Int"},{"key":"5663_CR13","doi-asserted-by":"publisher","unstructured":"Saito Y, Hayashi S, Gonmori T et al (2020) Interrupting tocilizumab therapy-induced psoriasis\u2010like eruption in a patient with rheumatoid arthritis and Crohn\u2019s disease. Int J Dermatol 59. https:\/\/doi.org\/10.1111\/ijd.14809","DOI":"10.1111\/ijd.14809"},{"key":"5663_CR14","doi-asserted-by":"publisher","unstructured":"Chen Y-T, Chang C-H (eds) (2021) (Miriam) Tocilizumab-induced psoriasis in a patient with rheumatoid arthritis: A case report and literature review. Dermatol Sin 39:89. https:\/\/doi.org\/10.4103\/ds.ds_57_20","DOI":"10.4103\/ds.ds_57_20"},{"key":"5663_CR15","first-page":"981","volume":"54","author":"S Suzuki","year":"2012","unstructured":"Suzuki S, Miyamoto A, Tada Y et al (2012) Case reports: psoriatic lesions appearing in a patient under tocilizumab therapy. Hihu Rinsho 54:981\u2013984","journal-title":"Hihu Rinsho"},{"key":"5663_CR16","unstructured":"World Health Organization (WHO)\u2014Uppsala Monitoring Centre The use of the WHO-UMC system for standardized case causality assessment"},{"key":"5663_CR17","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1002\/art.23835","volume":"59","author":"AN Collamer","year":"2008","unstructured":"Collamer AN, Guerrero KT, Henning JS, Battafarano DF (2008) Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action. Arthritis Rheum 59:996\u20131001. https:\/\/doi.org\/10.1002\/art.23835","journal-title":"Arthritis Rheum"},{"key":"5663_CR18","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1002\/cia2.12208","volume":"5","author":"S Sato","year":"2022","unstructured":"Sato S, Sawada Y, Nakamura M (2022) Sarilumab-induced cutaneous adverse event. J Cutan Immunol Allergy 5:67\u201368. https:\/\/doi.org\/10.1002\/cia2.12208","journal-title":"J Cutan Immunol Allergy"},{"key":"5663_CR19","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1158\/1078-0432.CCR-14-1678","volume":"21","author":"A Deisseroth","year":"2015","unstructured":"Deisseroth A, Ko C-W, Nie L et al (2015) FDA approval: Siltuximab for the treatment of patients with Multicentric Castleman Disease. Clin Cancer Res 21:950\u2013954. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-1678","journal-title":"Clin Cancer Res"},{"key":"5663_CR20","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.jbspin.2012.06.010","volume":"79","author":"J Rueda-Gotor","year":"2012","unstructured":"Rueda-Gotor J, Gonz\u00e1lez-Gay MA, Blanco Alonso R et al (2012) Successful effect of tocilizumab in anti-TNF-\u03b1-induced palmoplantar pustulosis in rheumatoid arthritis. Joint Bone Spine 79:510\u2013513. https:\/\/doi.org\/10.1016\/j.jbspin.2012.06.010","journal-title":"Joint Bone Spine"},{"key":"5663_CR21","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.3899\/jrheum.120304","volume":"39","author":"S Younis","year":"2012","unstructured":"Younis S, Rimar D, Slobodin G, Rosner I (2012) Tumor necrosis factor-associated palmoplantar pustular psoriasis treated with interleukin 6 blocker. J Rheumatol 39:2055\u20132056. https:\/\/doi.org\/10.3899\/jrheum.120304","journal-title":"J Rheumatol"},{"key":"5663_CR22","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41467-017-02466-4","volume":"9","author":"C Conrad","year":"2018","unstructured":"Conrad C, Di Domizio J, Mylonas A et al (2018) TNF blockade induces a dysregulated type I interferon response without autoimmunity in paradoxical psoriasis. Nat Commun 9:25. https:\/\/doi.org\/10.1038\/s41467-017-02466-4","journal-title":"Nat Commun"},{"key":"5663_CR23","doi-asserted-by":"publisher","first-page":"19674","DOI":"10.1038\/srep19674","volume":"6","author":"M Zimmermann","year":"2016","unstructured":"Zimmermann M, Arruda-Silva F, Bianchetto-Aguilera F et al (2016) IFN\u03b1 enhances the production of IL-6 by human neutrophils activated via TLR8. Sci Rep 6:19674. https:\/\/doi.org\/10.1038\/srep19674","journal-title":"Sci Rep"},{"key":"5663_CR24","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1051\/medsci\/20163203009","volume":"32","author":"A De Masson","year":"2016","unstructured":"De Masson A, Bouaziz J-D, Battistella M et al (2016) Immunopathologie Du psoriasis: from bench to bedside. m\u00e9decine\/sciences 32:253\u2013259. https:\/\/doi.org\/10.1051\/medsci\/20163203009","journal-title":"m\u00e9decine\/sciences"},{"key":"5663_CR25","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.jid.2016.11.022","volume":"137","author":"A Blauvelt","year":"2017","unstructured":"Blauvelt A (2017) IL-6 differs from TNF-\u03b1: unpredicted clinical effects caused by IL-6 blockade in Psoriasis. J Invest Dermatol 137:541\u2013542. https:\/\/doi.org\/10.1016\/j.jid.2016.11.022","journal-title":"J Invest Dermatol"},{"key":"5663_CR26","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/j.jid.2016.10.021","volume":"137","author":"Y Fritz","year":"2017","unstructured":"Fritz Y, Klenotic PA, Swindell WR et al (2017) Induction of Alternative Proinflammatory cytokines accounts for sustained psoriasiform skin inflammation in IL-17\u00a0C\u2009+\u2009IL-6KO mice. J Invest Dermatol 137:696\u2013705. https:\/\/doi.org\/10.1016\/j.jid.2016.10.021","journal-title":"J Invest Dermatol"},{"key":"5663_CR27","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.jbspin.2010.08.004","volume":"77","author":"L Brulhart","year":"2010","unstructured":"Brulhart L, Nissen MJ, Chevallier P, Gabay C (2010) Tocilizumab in a patient with ankylosing spondylitis and Crohn\u2019s disease refractory to TNF antagonists. Joint Bone Spine 77:625\u2013626. https:\/\/doi.org\/10.1016\/j.jbspin.2010.08.004","journal-title":"Joint Bone Spine"},{"key":"5663_CR28","doi-asserted-by":"publisher","first-page":"137","DOI":"10.3109\/14397595.2016.1174328","volume":"27","author":"S Muramatsu","year":"2017","unstructured":"Muramatsu S, Kubo R, Nishida E, Morita A (2017) Serum interleukin-6 levels in response to biologic treatment in patients with psoriasis. Mod Rheumatol 27:137\u2013141. https:\/\/doi.org\/10.3109\/14397595.2016.1174328","journal-title":"Mod Rheumatol"},{"key":"5663_CR29","doi-asserted-by":"publisher","unstructured":"de Oliveira PSS, Cardoso PRG, Lima EV de A et al (2015) IL-17A, IL-22, IL-6, and IL-21 serum levels in plaque-type psoriasis in Brazilian patients. Mediators Inflamm 2015(819149). https:\/\/doi.org\/10.1155\/2015\/819149","DOI":"10.1155\/2015\/819149"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-024-05663-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-024-05663-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-024-05663-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T02:04:12Z","timestamp":1726193052000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00296-024-05663-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,16]]},"references-count":29,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,10]]}},"alternative-id":["5663"],"URL":"https:\/\/doi.org\/10.1007\/s00296-024-05663-9","relation":{},"ISSN":["1437-160X"],"issn-type":[{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,16]]},"assertion":[{"value":"13 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval for this case was obtained from IRB 00013918 direction de la formation, de la recherche et de l\u2019innovation* \u2013 DFRI IRB #1 (IORG0011755). Written informed consent was obtained for anonymized patient information to be published in this article, including the publication of the pictures.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"none (A-C Fougerousse has received consulting fees, lecture honoraria and support for attending meeting, and has participated on data safety monitoring board for Abbvie, Janssen, Leo Pharma, Lilly, Novartis, UCB Pharma and Almirall, not relied to the present publication).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}